JOHN STAHLMAN: Open Payments
NPI 1811006273 · ASHEVILLE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,663 in 92 payments from 13 companies in 2025. Trend: 2023 $993 · 2024 $971 · 2025 $1,663
Food & beverage: $1,663
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 32 | $484 |
| Neurocrine BioSciences, Inc. | 12 | $240 |
| ABBVIE INC. | 15 | $221 |
| E.R. Squibb & Sons, L.L.C. | 7 | $162 |
| Otsuka America Pharmaceutical, Inc. | 6 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Vanda Pharmaceuticals Inc. | 4 | $91 |
| Axsome Therapeutics, Inc. | 3 | $87 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| Alkermes, Inc. | 3 | $48 |
Products named: AUSTEDO XR, INGREZZA, VRAYLAR, COBENFY, UZEDY, REXULTI, CAPLYTA, FANAPT.
Industry payments across NC — which companies pay providers there.
